Among the cohort of pancreatic cancer patients receiving higher doses of the treatment, 93% experienced a significant reduction in key tumor markers. Side effects remained largely limited to mild gastrointestinal issues like nausea and diarrhea, which typically subsided following the initial cycle of therapy. These preliminary results suggest the drug may offer a viable path for patients who have historically faced limited treatment options.

Verastem intends to expand the scope of its research by evaluating VS-7375 in combination with a separate experimental therapy currently in development by Erasca. The company plans to release a more comprehensive update on the VS-7375 program before the end of the year.